


Bring RenThyroid to Your Practice

Explore detailed information about RenThyroid, and how it can support your patients with hypothyroidism.



Visit Our Website:

Scan the QR code or visit www.renthyroid.com



RenThyroid is the medication I wish I had as a patient—now, it's my choice for my patients.

- McCall McPherson, PA-C
Paid Consultant for RenThyroid



INDICATIONS:

RenThyroid™ (Thyroid Tablets, USP) is a prescription oral medication indicated as replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis.

Note: RenThyroid has not been reviewed by the FDA for safety or efficacy.

IMPORTANT SAFETY INFORMATION:

DRUGS WITH THYROID HORMONE ACTIVITY, ALONE OR TOGETHER WITH OTHER THERAPEUTIC AGENTS, HAVE BEEN USED FOR THE TREATMENT OF OBESITY. IN EUTHYROID PATIENTS, DOSES WITHIN THE RANGE OF DAILY HORMONAL REQUIREMENTS ARE INEFFECTIVE FOR WEIGHT REDUCTION. LARGER DOSES MAY PRODUCE SERIOUS OR EVEN LIFE-THREATENING MANIFESTATIONS OF TOXICITY, PARTICULARLY WHEN GIVEN IN ASSOCIATION WITH SYMPATHOMIMETIC AMINES SUCH AS THOSE USED FOR THEIR ANORECTIC EFFECTS.

CONTRAINDICATIONS:

RenThyroid is contraindicated in patients with uncorrected adrenal cortical insufficiency, untreated thyrotoxicosis, and/or hypersensitivity to any of component of the product.

WARNINGS AND PRECAUTIONS:

Cardiovascular System. Thyroid hormones should be used with caution in the presence of cardiovascular risks, and particularly coronary artery risks. Patients with angina pectoris and elderly patients present increased risks. Initiate treatment with low doses (15–30 mg). Worsening cardiovascular disease may require reduced dose or discontinuation.

Diabetes and Adrenal Disorders. In patients with concomitant diabetes mellitus, diabetes insipidus, or adrenal cortical insufficiency, thyroid hormones aggravate symptoms of these conditions. Adjust treatment for these concomitant endocrine diseases as appropriate. Treatment of myxedema coma requires simultaneous administration of glucocorticoids.

Oral Anticoagulants. Hypothyroidism decreases and hyperthyroidism increases sensitivity to oral anticoagulants. For patients taking thyroid hormones and oral anticoagulants, prothrombin time and dose should be closely monitored and adjusted based on frequent prothrombin time determinations.

Infant Craniosynostosis. In infants, excessive doses of thyroid hormones may produce craniosynostosis.

ADVERSE REACTIONS:

Adverse reactions other than those indicative of hyperthyroidism because of therapeutic overdosage, either initially or during the maintenance period, are rare. Excessive doses of thyroid result in a hypermetabolic state. In case of overdosage, temporarily discontinue treatment. Treatment may be reinstated at a lower dosage.

DRUG INTERACTIONS:

Oral Anticoagulants. Concomitant use of thyroid hormones with oral anticoagulants alters the sensitivity of oral anticoagulants.

Insulin or Oral Hypoglycemics. Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. Patients receiving insulin or oral hypoglycemics should be closely monitored during initiation of thyroid replacement therapy.

Cholestyramine or Colestipol. Cholestyramine or colestipol binds both levothyroxine (T4) and liothyronine (T3) in the intestine, impairing their absorption. Allow 4 to 5 hours between the administration of cholestyramine or colestipol and thyroid hormones.

Estrogen, Oral Contraceptives. Estrogens tend to increase serum thyroxine-binding globulin (TBG), decreasing free levothyroxine (T4). Patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if taking estrogen or estrogen-containing oral contraceptives.

Drug/Laboratory Test Interactions. Certain drugs or moieties interfere with laboratory tests performed in patients on thyroid hormone therapy: androgens, corticosteroids, estrogens, oral contraceptives containing estrogens, iodine-containing preparations, biotin, and preparations containing salicylates.

For complete safety information, please see the full [Prescribing Information](#).

To report suspected adverse reactions, contact Genus Lifesciences at 1-610-782-9780 or Info@GenusLifesciences.com or FDA at www.fda.gov/medwatch or call 1-800-FDA-1088.

References:

1. Wyne KL, Nair L, Schneiderman CP, et al. Hypothyroidism Prevalence in the United States: A Retrospective Study Combining National Health and Nutrition Examination Survey and Claims Data, 2009-2019. *J Endocr Soc.* 2022;7(1):bvac172. Published 2022 Nov 10. doi:10.1210/endo/bvac172
2. McAninch EA, Bianco AC. The swinging pendulum in treatment for hypothyroidism: from (and toward?) combination therapy. *Front Endocrinol.* 2019;10:446. doi:10.3389/fendo.2019.00446
3. RenThyroid [prescribing information]. Allentown, PA: Genus Lifesciences, Inc. 2024.



RenThyroid™

(Thyroid Tablets, USP)

RenThyroid has not been reviewed by the FDA for safety or efficacy.



Actor Portrayal

When the **Numbers Look Right**,
But They Still **Don't Feel Right...**

RenThyroid™ (Thyroid Tablets, USP)

Provides Another Option

A Natural Desiccated Thyroid (NDT)
containing both T3 and T4 hormones.


RenThyroid is a prescription medicine indicated as a replacement or supplemental therapy in patients with hypothyroidism.

Please see Important Safety Information, including Boxed Warning, on back and accompanying Full Prescribing Information.



Genus Lifesciences, Inc. | genuslifesciences.com
514 North 12th Street, Allentown, PA 18102 | 610-782-9780

Genus Lifesciences, RenThyroid, and their associated logos are trademarks of Genus Lifesciences, Inc. All rights reserved. | REN-0801-0004 Rev. 03/2025



Actor Portrayal

Beyond Lab Results: Addressing Persistent Symptoms

Hypothyroidism Affects
30 Million
Adults¹

10-15% of patients on T4 monotherapy still experience symptoms like fatigue, weight gain, and low energy.²

Hypothyroid care isn't just about normalizing lab values — it's about the **whole patient experience**.

Support Patients Who Still Feel the Effects of Hypothyroidism

If your patients are still experiencing symptoms despite their lab results being in the normal range, RenThyroid may offer the support they need.

WARNING:

DRUGS WITH THYROID HORMONE ACTIVITY, ALONE OR TOGETHER WITH OTHER THERAPEUTIC AGENTS, HAVE BEEN USED FOR THE TREATMENT OF OBESITY. IN EUTHYROID PATIENTS, DOSES WITHIN THE RANGE OF DAILY HORMONAL REQUIREMENTS ARE INEFFECTIVE FOR WEIGHT REDUCTION. LARGER DOSES MAY PRODUCE SERIOUS OR EVEN LIFE-THREATENING MANIFESTATIONS OF TOXICITY, PARTICULARLY WHEN GIVEN IN ASSOCIATION WITH SYMPATHOMIMETIC AMINES SUCH AS THOSE USED FOR THEIR ANORECTIC EFFECTS.

Please see additional Important Safety Information on back and accompanying Full Prescribing Information

Why Consider RenThyroid

RenThyroid is a **NDT** that contains a fixed ratio of **T3 and T4 hormones**, closely matching the natural hormone balance in the thyroid gland.³

NDT from a Trusted, Quality Source



Made with only
4 inactive ingredients³



Each batch tested for quality
and potency according to
FDA standards



Dye-free and free of
gluten-containing grains
like wheat, barley, and rye³



Manufactured in a U.S.-based,
FDA-inspected Genus Lifesciences facility



A natural thyroid product from
a U.S.-based natural source

Available in 5 Strengths for Flexible Dosing

Tailor **RenThyroid** to Each Patient

15 mg

30 mg


60 mg

90 mg

120 mg



100 Tablets Per Bottle



T3 and T4 in One Tablet

RenThyroid contains a fixed ratio of T3
and T4 hormones, in one tablet.³

CONTRAINDICATIONS:

RenThyroid is contraindicated in patients with uncorrected adrenal cortical insufficiency, untreated thyrotoxicosis, and/or hypersensitivity to any of component of the product.